Displaying drugs 13426 - 13450 of 15170 in total
Carbon black
Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment with demonstrated adverse effects on pulmonary function. Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue and has been linked to carcinogenicity.[A263406, A263411, A263416]
Investigational
Matched Description: … inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and …
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
MVA3000
MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or skin conditions such as eczema.
Investigational
NUC B1000
NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid delivery system. eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to...
Investigational
IDD-3
IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells.
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
HSV-2 theracine
HSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Investigational
Q-Derp1
Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
Investigational
TRX1
TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
Investigational
FAV-201
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Investigational
Gavilimomab
Investigational
(2S)-2-(1H-indol-3-yl)hexanoic acid
Experimental
Liquidambar styraciflua resin
Experimental
Insulin argine
Experimental
Placulumab
Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
Glucagon-like peptide II
Glucagon-like peptide II is under investigation for the basic science of Short Bowel Syndrome.
Investigational
Denenicokin
Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
Investigational
Disitertide
Disitertide has been used in trials studying the treatment of Skin Fibrosis.
Investigational
Clostridium botulinum
Experimental
Lactobacillus reuteri
Experimental
Investigational
Aloe vera leaf polysaccharides
Experimental
Sus scrofa placenta
Sus scrofa placenta is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Pearl (hyriopsis cumingii)
Pearl (hyriopsis cumingii) is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Displaying drugs 13426 - 13450 of 15170 in total